AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $10.88 billion versus the consensus estimate of $10.69 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.